Search results
Showing 1786 to 1800 of 1996 results for nice guidelines
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
Evidence-based recommendations on pemigatinib (Pemaryze) for relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement in adults.
Obinutuzumab with mycophenolate mofetil for treating lupus nephritis (TA1131)
Evidence-based recommendations on obinutuzumab (Gazyvaro) with mycophenolate mofetil for treating lupus nephritis in adults.
PredictSURE IBD and IBDX to guide treatment of Crohn's disease (HTG610)
Evidence-based recommendations on PredictSURE IBD and IBDX for guiding treatment of Crohn’s disease.
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
superDimension Navigation System to help diagnostic sampling of peripheral lung lesions (MIB194)
NICE has developed a medtech innovation briefing (MIB) on superDimension Navigation System to help diagnostic sampling of peripheral lung lesions .
Our board sets out our strategic priorities and policies. It has 2 sub-committees, the audit and risk assurance committee and the remuneration committee.
One-piece closed bags for colostomies: late-stage assessment (HTG754)
Late stage assessment (LSA) guidance on one-piece closed bags for colostomies
View recommendations for HTG754Show all sections
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults.
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults.
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
NICE has developed a medtech innovation briefing (MIB) on the Epidrum for aiding access to the epidural space